Argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy

Independent Data Monitoring Committee recommended study continuation based on the favorable safety profile observed in the first dose cohortEarly efficacy signals support proof-of-concept of... | June 20, 2023

Related Keywords

Netherlands ,Amsterdam ,Noord Holland ,Japan ,United Kingdom ,Erin Murphy ,Luc Truyen ,Linkedin ,Instagram ,Immunology Innovation Program ,Twitter ,Data Monitoring Committee ,Independent Data Monitoring Committee ,Chief Medical Officer ,